Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: Relationship to pharmacodynamic effects

Addiction Biology

Volumn 21, Issue 2, 2016, Pages 339-347

  Anizan, Sebastien ^a   Concheiro, Marta ^a   Lehner, Kurt R ^a   Bukhari, Mohammad O ^a   Suzuki, Masaki ^a   Rice, Kenner C ^a   Baumann, Michael H ^a   Huestis, Marilyn A ^a,b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

bath salts; designer drugs; MDPV; metabolites; PK PD; synthetic cathinones

Indexed keywords

3,4 DIHYDROXYPYROVALERONE; 3,4 METHYLENE DIOXYPYROVALERONE; 4 HYDROXY 3 METHOXYPYROVALERONE; CATHINONE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; DESIGNER DRUG; DOPAMINE UPTAKE INHIBITOR; PSYCHOTROPIC AGENT; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

ANIMALS; BENZODIOXOLES; DESIGNER DRUGS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; PSYCHOTROPIC DRUGS; PYRROLIDINES; RATS, SPRAGUE-DAWLEY;

EID: 84959228187     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12201     Document Type: Article

References (36)

1. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA, (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology 71: 130-140.
2. Anizan S, Ellefsen K, Concheiro M, Suzuki M, Rice KC, Baumann MH, Huestis MA, (2014) 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. Anal Chim Acta 827: 54-63.
3. Baumann M, Zolkowska D, Kim I, Scheidweiler K, Rothman R, Huestis M, (2009) Effects of dose and route of administration on pharmacokinetics of (+or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37: 2163-2170.
4. Baumann MH, Clark RD, Franken FH, Rutter JJ, Rothman RB, (2008) Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 152: 773-784.
5. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB, (2011) In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218-225.
6. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW, (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 38: 552-562.
7. Borek HA, Holstege CP, (2012) Hyperthermia and multiorgan failure after abuse of 'bath salts' containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 60: 103-105.
8. Cameron KN, Kolanos R, Solis E Jr., Glennon RA, De Felice LJ, (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168: 1750-1757.
9. Chu T, Kumagai Y, DiStefano EW, Cho AK, (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51: 789-796.
10. Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA, (2013) Nonlinear Pharmacokinetics of ({±})3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos 42: 119-125.
11. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J, (2004) Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137-144.
12. Drug Enforcement Administration (DEA), Department of Justice (2013) Establishment of drug codes for 26 substances. Final Rule. Fed Regist 78: 664-666.
13. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC, (2013) In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38: 563-573.
14. Gatch MB, Taylor CM, Forster MJ, (2013) Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24: 437-447.
15. Gregg RA, Rawls SM, (2014) Behavioral pharmacology of designer cathinones: A review of the preclinical literature. Life Sci 97: 27-30.
16. Gunderson EW, Kirkpatrick MG, Willing LM, Holstege CP, (2013) Substituted cathinone products: A new trend in 'bath salts' and other designer stimulant drug use. J Addict Med 7: 153-162.
17. Hartman RL, Desrosiers NA, Barnes AJ, Yun K, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA, (2013) 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. Anal Bioanal Chem 406: 587-599.
18. Huestis MA, de Martinis BS, Goodwin RS, Gorelick DA, (2007) Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. In: The International Association of Therapeutic Drug Monitoring and Clinical Toxicology Annual Meeting-2007: Nice, France.
19. Ikemoto S, (2002) Ventral striatal anatomy of locomotor activity induced by cocaine, D-amphetamine, dopamine and D1/D2 agonists. Neuroscience 113: 939-955.
20. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuchihashi H, (2006) Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36: 709-723.
21. Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR, (2013) Methylenedioxypyrovalerone ('bath salts'), related death: Case report and review of the literature. J Forensic Sci 58: 1654-1659.
22. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA, (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30: 320-332.
23. Kyle PB, Iverson RB, Gajagowni RG, Spencer L, (2011) Illicit bath salts: Not for bathing. J Miss State Med Assoc 52: 375-377.
24. Lopez-Arnau R, Martinez-Clemente J, Carbo M, Pubill D, Escubedo E, Camarasa J, (2013) An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as 'bath salts. Prog Neuropsychopharmacol Biol Psychiatry 45: 64-72.
25. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH, (2014) Pharmacology of novel synthetic stimulants structurally related to the 'bath salts' constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87: 206-213.
26. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT, (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113: 133-142.
27. Meltzer PC, Butler D, Deschamps JR, Madras BK, (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
28. Meyer MR, Du P, Schuster F, Maurer HH, (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 45: 1426-1442.
29. Mueller DM, Rentsch KM, (2012) Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identification by LC-MS(n), and metabolism of 11 cathinones. Anal Bioanal Chem 402: 2141-2151.
30. Pedersen AJ, Reitzel LA, Johansen SS, Linnet K, (2013) In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 5: 430-438.
31. Pennartz CM, Groenewegen HJ, Lopes da Silva FH, (1994) The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol 42: 719-761.
32. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME, (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458-470.
33. Spiller HA, Ryan ML, Weston RG, Jansen J, (2011) Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49: 499-505.
34. Strano-Rossi S, Cadwallader AB, de la Torre X, Botre F, (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24: 2706-2714.
35. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF, (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19: 165-174.
36. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH, (2009) Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.